2026-08-05T15:45:59Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/138832024-11-29T21:48:13Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Kartal, Ece author Schmidt, Thomas S B author Wirbel, Jakob author Maistrenko, Oleksandr M author Akanni, Wasiu A author Alashkar Alhamwe, Bilal author Alves, Renato J author Carrato, Alfredo author Erasmus, Hans-Peter author Estudillo, Lidia author Finkelmeier, Fabian author Fullam, Anthony author Glazek, Anna M author Gómez-Rubio, Paulina author Hercog, Rajna author Jung, Ferris author Kandels, Stefanie author Kersting, Stephan author Langheinrich, Melanie author Márquez, Mirari author Molero, Xavier author Orakov, Askarbek author Van Rossum, Thea author Raul, Torres-Ruiz author Telzerow, Anja author Zych, Konrad author Benes, Vladimir author Zeller, Georg author Trebicka, Jonel author Bork, Peer author Malats, Nuria author Molina-Montes, Esther author Rodriguez Perales, Sandra author Real Arribas, Francisco author 2022-03-08 Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. To explore the faecal and salivary microbiota as potential diagnostic biomarkers. We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case-control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case-control study (n=76), in the validation phase. Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19-9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible. Gut . 2022 Mar 8;gutjnl-2021-324755. 10.1136/gutjnl-2021-324755 1468-3288 Gut 35260444 http://hdl.handle.net/20.500.12105/13883 HUMAN GUT MICROBIOME REAL-TIME PCR TUMOR MICROBIOME ORAL MICROBIOTA DIVERSITY ASSOCIATION BIOMARKERS METAGENOME A faecal microbiota signature with high specificity for pancreatic cancer.